Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cornberg

Showing results (321-330 of 350) with videos related to

Pageof 35
Sort By:
The Lancet. Infectious Diseases|March 6, 2019
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trialHeiner Wedemeyer, Cihan Yurdaydin, Svenja Hardtke, et al.
Advances in Therapy|October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated CirrhosisMarkus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
Cell Genomics|December 7, 2022
Altered and allele-specific open chromatin landscape reveals epigenetic and genetic regulators of innate immunity in COVID-19Bowen Zhang, Zhenhua Zhang, Valerie A C M Koeken, et al.
Nature Immunology|January 14, 2026
A distinct monocyte transcriptional state links systemic immune dysregulation to pulmonary impairment in long COVIDSaumya Kumar, Chaofan Li, Liang Zhou, et al.
Gut|April 15, 2026
CD16<sup>+</sup> γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infectionPaulina E Schröter, Katja Steppich, Laura Fernández Carrera, et al.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 27, 2025
Extrahepatic Replication and Genomic Signatures of the Hepatitis E Virus in the KidneyAvista Wahid, Nele Meyer, Christine Wundes, et al.
Journal of Hepatology|January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|April 16, 2023
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis BFlorian van Bömmel, Kerstin Stein, Renate Heyne, et al.
Gastroenterology|February 16, 2019
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8<sup>+</sup> T Cells and Evolve at the Population LevelHadi Karimzadeh, Muthamia M Kiraithe, Valerie Oberhardt, et al.
Pageof 35

Showing results (321-330 of 350) with videos related to

Sort By:
Pageof 35
The Lancet. Infectious Diseases|March 6, 2019
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trialHeiner Wedemeyer, Cihan Yurdaydin, Svenja Hardtke, et al.
Advances in Therapy|October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated CirrhosisMarkus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
Cell Genomics|December 7, 2022
Altered and allele-specific open chromatin landscape reveals epigenetic and genetic regulators of innate immunity in COVID-19Bowen Zhang, Zhenhua Zhang, Valerie A C M Koeken, et al.
Nature Immunology|January 14, 2026
A distinct monocyte transcriptional state links systemic immune dysregulation to pulmonary impairment in long COVIDSaumya Kumar, Chaofan Li, Liang Zhou, et al.
Gut|April 15, 2026
CD16<sup>+</sup> γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infectionPaulina E Schröter, Katja Steppich, Laura Fernández Carrera, et al.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 27, 2025
Extrahepatic Replication and Genomic Signatures of the Hepatitis E Virus in the KidneyAvista Wahid, Nele Meyer, Christine Wundes, et al.
Journal of Hepatology|January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|April 16, 2023
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis BFlorian van Bömmel, Kerstin Stein, Renate Heyne, et al.
Gastroenterology|February 16, 2019
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8<sup>+</sup> T Cells and Evolve at the Population LevelHadi Karimzadeh, Muthamia M Kiraithe, Valerie Oberhardt, et al.
Pageof 35